Hospira (NYSE: HSP) is expected to report Q2 earnings on July 31. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Hospira's revenues will drop -0.8% and EPS will compress 0.0%.

The average estimate for revenue is $1.03 billion. On the bottom line, the average EPS estimate is $0.51.

Revenue details
 Last quarter, Hospira notched revenue of $988.3 million. GAAP reported sales were 8.5% lower than the prior-year quarter's $965.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.52. GAAP EPS were -$0.46 for Q1 compared to $0.24 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 17.4%, much worse than the prior-year quarter. Operating margin was -11.8%, much worse than the prior-year quarter. Net margin was -8.7%, much worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $4.06 billion. The average EPS estimate is $2.03.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 138 members out of 167 rating the stock outperform, and 29 members rating it underperform. Among 49 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 40 give Hospira a green thumbs-up, and nine give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hospira is hold, with an average price target of $30.54.